Taha Reşid ÖZDEMİR, Mustafa EMİROĞLU, Mustafa DEĞİRMENCİ, Özge ÖZER KAYA, Berk ÖZYILMAZ, Özgür KIRBIYIK, Altuğ KOÇ, Kadri Murat ERDOĞAN, Merve SAKA GÜVENÇ, Gönül DEMİR

The Frequency and Management of TP53 Mutation Carriers in Turkish Patients with BRCA-Negative Breast Cancer Under 50 Years of Age

OBJECTIVEGermline mutations in the TP53 gene cause Li-Fraumeni Syndrome (LFS). Breast cancer (BC) is the most common cancer that is seen in young women with LFS. The majority of BC in LFS occurs between 15 and 44 age of years. The present study aims to determine the frequency of TP53 gene germline muta-tion carriers in Turkish patients with BRCA-negative BC under 50 years of age as the first study from Turkey, to our knowledge, and to emphasize the importance of management in TP53 gene mutation carriers.METHODSOne hundred patients with BRCA-negative BC younger than 50 years old were evaluated concerning mutations in the TP53 gene between 2016 and 2017 years. Sequencing analysis using targeted next-gen-eration sequencing (NGS) and deletion/duplication analysis using multiplex ligation-dependent probe amplification (MLPA) method were performed in TP53 gene in all patients.RESULTSFive variants were identified in five of 100 patients (5%) in this study. Four of them were evaluated as known as pathogenic/likely pathogenic (4%; 4/100). One variant was evaluated as a variant of uncertain clinical significance (VUS).CONCLUSIONThe patients with BRCA-negative BC younger than 50 years old should be evaluated concerning TP53 gene mutations because of increased lifetime risk of various developing cancer. Appropriate genetic counseling should be given to patients with TP53 gene mutations, and the follow-up of these patients should be provided multidisciplinary.

PDF

___

1. Yang X, Wu J, Lu J, Liu G, Di G, Chen C, et al. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS One 2015;10(4):e0125571.
2. Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat 2018;167(2):417–23.
3. Salmon A, Amikam D, Sodha N, Davidson S, BaselVanagaite L, Eeles RA, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline ‘de-novo’ TP53 mutation. Clin Oncol (R Coll Radiol) 2007;19(7):490–3.
4. Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, et al. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 2009;8(4):563–7.
5. Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, et al. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Re. 2012;14(2):R66.
6. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol 2011;29(1):24–6.
7. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14(2):178–92.
8. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17(5):405–24.
9. Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat 2016;37(9):865–76.
10. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014;11(4):361–2.
11. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7(4):248–9.
12. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4(7):107381.
13. Desmet FO, Hamroun D, Lalande M, Collod-Béroud G, Claustres M, Béroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009;37(9):e67.
14. Lindor NM, McMaster ML, Lindor CJ, Greene MH; National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008;(38):1–93.
15. Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, et al. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing. J Natl Cancer Inst 2018;110(8):863–70.
16. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol 2015;33(21):2345–52.
17. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of earlyonset breast cancer: Australian Breast Cancer Family Study. Cancer Res 2010;70(12):4795–800.
18. Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer 2016;122(23):3673–81.
19. Lalloo F, Varley J, Moran A, Ellis D, O’dair L, Pharoah P, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer 2006;42(8):1143–50.
20. Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, et al. Molecular basis of the LiFraumeni syndrome: an update from the French LFS families. J Med Genet 2008;45(8):535–8.
21. Gonzalez KD, Noltner KA, Buzin CH, Gu D, WenFong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27(8):1250–6.
22. Rashid MU, Gull S, Asghar K, Muhammad N, Amin A, Hamann U. Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Fam Cancer 2012;11(2):307–11.
23. Carraro DM, Koike Folgueira MA, Garcia Lisboa BC, Ribeiro Olivieri EH, Vitorino Krepischi AC, de Car valho AF, et al. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil. PLoS One 2013;8(3):e57581.
24. Gallardo-Alvarado LN, Tusié-Luna MT, Tussié-Luna MI, Díaz-Chávez J, Segura YX, Bargallo-Rocha E, et al. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population. BMC Cancer 2019;19(1):118.
25. Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res 2017;23(11):e38–e45.
26. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy f ields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96(4):238–42.
27. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010;5:104.
28. Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, et al. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol 2017;3(12):1634–9.